22nd Century Group (NASDAQ:XXII) Upgraded by Wall Street Zen to Sell Rating

22nd Century Group (NASDAQ:XXII) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings raised shares of 22nd Century Group from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, 22nd Century Group presently has an average rating of “Sell”.

22nd Century Group Stock Performance

NASDAQ:XXII opened at $3.93 on Friday. The firm has a market capitalization of $864,600.00, a PE ratio of -0.00 and a beta of 0.63. The stock’s fifty day moving average is $16.41 and its 200 day moving average is $108.97. 22nd Century Group has a fifty-two week low of $3.86 and a fifty-two week high of $2,841.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.67.

22nd Century Group (NASDAQ:XXII) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($101.40) EPS for the quarter, missing the consensus estimate of ($24.00) by ($77.40). The firm had revenue of $4.11 million for the quarter, compared to analysts’ expectations of $4.61 million. 22nd Century Group had a negative return on equity of 84.37% and a negative net margin of 25.34%.

Institutional Investors Weigh In On 22nd Century Group

An institutional investor recently bought a new position in 22nd Century Group stock. Geode Capital Management LLC acquired a new stake in shares of 22nd Century Group, Inc (NASDAQ:XXII) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 46,491 shares of the biotechnology company’s stock, valued at approximately $36,000. Geode Capital Management LLC owned 9.12% of 22nd Century Group as of its most recent SEC filing. 18.06% of the stock is currently owned by institutional investors.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.